serodiagnosis
PreclinicalBiologic
serodiagnosis is one of 13 biologic programs targeting Graves disease. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Graves Disease
#DrugCompanyPhaseTrials
1Tapazole
VViking Therapeutics, Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Synthroid
IInstitut Jerome Lejeune
Approved
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Efgartigimod PH20 SC
ArgenxPhase 3
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
IMVT-1402
IImmunovant Sciences GmbH
Phase 2
BHV-1300
BBiohaven Therapeutics Ltd.
Phase 3
Allogeneic CAR-T
TThe First Affiliated Hospital with Nanjing Medical University
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Graves disease1 trial
Prevalence of Circulating Parvovirus Genome in Recently Diagnosed Graves' Disease: a Case-control Study
Completed·—·N/A·NCT02798965·52 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for serodiagnosis. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details